Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

Abstract Background To examine the efficacy and safety of induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin (ISMT) in Japanese patients with HER2-negative metastatic breast cancer (MBC). Methods Patients, who had previously undergone a maximum of...

Full description

Bibliographic Details
Main Authors: Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Kei Kimizuka, Masafumi Kurosumi
Format: Article
Language:English
Published: BMC 2018-06-01
Series:BMC Cancer
Subjects:
Metastatic breast cancer
Eribulin
Paclitaxel
Bevacizumab
Switch maintenance therapy
Metastasis
Online Access:http://link.springer.com/article/10.1186/s12885-018-4556-6

Internet

http://link.springer.com/article/10.1186/s12885-018-4556-6

Similar Items